臨床腫瘍学の次世代シーケンサーの市場規模、シェア、成長分析：技術別、ワークフロー別、用途別、最終用途別、地域別 - 産業予測 2025～2032年

臨床腫瘍学次世代シーケンサーの世界市場規模は、2023年に3億8,000万米ドルと評価され、2024年の4億4,042万米ドルから2032年には14億3,395万米ドルに成長し、予測期間（2025年～2032年）のCAGRは15.9%で成長する見通しです。

次世代シーケンシング（NGS）は、包括的なゲノム解析のためのスケーラブルな高スループットソリューションを提供することで、臨床腫瘍学に革命をもたらしています。この高度なシーケンス技術により、希少がんや新規がん変異の同定が可能になり、家族間の遺伝性がんリスクの検出が容易になり、個々の患者に合わせた標的療法の選択に役立ちます。NGSプロセスの鍵はDNAプレシークエンシングであり、これは正確なシークエンシング結果を得るためのサンプル調製を行います。当社のプラットフォームは、生データを解析してゲノムの変化を分類し、既存の実験的治療や承認された治療との相関関係を解釈することにより、NGSの臨床的有用性を高めます。その結果、NGSデータ処理システムの統合は、個別化された腫瘍学的治療を提供するためにますます不可欠となり、医療従事者はゲノムの洞察に基づいて十分な情報に基づいた治療決定を行うことができるようになります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ分析

臨床腫瘍学次世代シーケンサーの市場規模：技術別

• 市場概要
• 全ゲノム配列解析
• 全エクソーム配列解析
• ターゲットシーケンシングとリシーケンシング

臨床腫瘍学次世代シーケンサーの市場規模：ワークフロー別

• 市場概要
• NGSプレシーケンス
• NGSシーケンシング
• NGSデータ解析

臨床腫瘍学次世代シーケンサーの市場規模：用途別

• 市場概要
• スクリーニング
• 散発性がん
• 遺伝性がん
• コンパニオン診断
• その他の診断

臨床腫瘍学次世代シーケンサーの市場規模：最終用途別

• 市場概要
• 病院
• クリニック
• 研究所

臨床腫瘍学次世代シーケンサーの市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Illumina, Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• F. Hoffmann-La Roche AG（Switzerland）
• Qiagen N.V.（Netherlands）
• Agilent Technologies, Inc.（US）
• BGI Genomics Co., Ltd.（China）
• PerkinElmer, Inc.（US）
• Oxford Nanopore Technologies, Inc.（UK）
• Pacific Biosciences of California, Inc.（US）
• Eurofins Scientific SE（Luxembourg）
• Myriad Genetics, Inc.（US）
• Guardant Health, Inc.（US）
• Natera, Inc.（US）
• Biocartis Group NV（Belgium）

結論と推奨事項

Global Clinical Oncology Next Generation Sequencing Market size was valued at USD 380.0 million in 2023 and is poised to grow from USD 440.42 million in 2024 to USD 1433.95 million by 2032, growing at a CAGR of 15.9% during the forecast period (2025-2032).

Next Generation Sequencing (NGS) is revolutionizing clinical oncology by offering scalable, high-throughput solutions for comprehensive genomic analysis. This advanced sequencing technology enables the identification of rare and novel cancer mutations, facilitates the detection of hereditary cancer risk among family members, and informs the selection of targeted therapies tailored to individual patients. Key to the NGS process is DNA pre-sequencing, which prepares samples for accurate sequencing outcomes. Our platform enhances the clinical utility of NGS by analyzing raw data to categorize and interpret genomic alterations in correlation with existing experimental and approved treatments. Consequently, the integration of NGS data processing systems is increasingly vital for delivering personalized oncology care, empowering healthcare professionals to make informed treatment decisions based on genomic insights.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Oncology Next Generation Sequencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Clinical Oncology Next Generation Sequencing Market Segmental Analysis

Global Clinical Oncology Next Generation Sequencing Market is segmented by Technology, Workflow, Application, End-use and region. Based on Technology, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing. Based on Workflow, the market is segmented into NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis. Based on Application, the market is segmented into Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics and Other Diagnostics. Based on End-use, the market is segmented into Hospitals, Clinics and Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is experiencing significant growth driven by advancements in research and technology. The rising demand for NGS technologies aligns with the growing emphasis on personalized medicine and companion diagnostics. Additionally, the expansion of NGS applications in liquid biopsy-specifically for sequencing circulating tumor DNA-promises to enhance revenue generation in the sector by facilitating non-invasive cancer profiling and real-time monitoring. Furthermore, increased funding for oncology research is contributing to the market's expansion, as innovative research programs and technological advancements continue to propel the utilization of NGS in clinical oncology settings.

Restraints in the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market faces significant constraints primarily due to the high costs involved. Patients worldwide struggle with the exorbitant expenses associated with this advanced clinical oncology process, creating substantial barriers to access. Ongoing economic challenges and political instability in various countries raise doubts about the sustainability of public healthcare funding. Furthermore, the lack of effective and affordable cancer treatments negatively affects population health, particularly in low-income nations, leading to decreased life expectancy. The high costs of consumables and specialized equipment for treating rare cancers further exacerbate the situation, stifling market growth and limiting accessibility.

Market Trends of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is poised for significant growth driven by the rising adoption of NGS in liquid biopsies, which enable the non-invasive sequencing of circulating tumor DNA. This technology allows for efficient tumor profiling and real-time cancer surveillance, addressing the urgent need for innovative diagnostic solutions. The advanced capabilities of NGS have evolved to facilitate simultaneous sequencing of multiple genomes, enhancing its appeal among laboratories for routine diagnostics. Factors such as accelerated processing speed, increased sensitivity, and reduced cost per sample are further propelling the market as providers leverage NGS to advance cancer research and patient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

Global Clinical Oncology Next Generation Sequencing Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

Global Clinical Oncology Next Generation Sequencing Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Laboratories

Global Clinical Oncology Next Generation Sequencing Market Size & CAGR (2025-2032)

• North America (Technology, Workflow, Application, End-use)
  • US
  • Canada
• Europe (Technology, Workflow, Application, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Workflow, Application, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Workflow, Application, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Workflow, Application, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies, Inc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocartis Group NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations